about
ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferationOpportunities for model-based precision dosing in the treatment of sickle cell anemia.Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment.Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case Report.What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosisDeferasirox: Over a Decade of Experience in Thalassemia
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical pharmacology of deferasirox.
@en
type
label
Clinical pharmacology of deferasirox.
@en
prefLabel
Clinical pharmacology of deferasirox.
@en
P2860
P1476
Clinical pharmacology of deferasirox.
@en
P2093
Chiaki Tanaka
P2860
P2888
P304
P356
10.1007/S40262-014-0151-4
P577
2014-08-01T00:00:00Z
P6179
1022276302